Could a common arthritis drug slow down multiple myeloma?
NCT ID NCT04370483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested leflunomide, an anti-inflammatory drug, in one patient with high-risk smoldering multiple myeloma. The goal was to see if the drug could delay progression to active myeloma. The study focused on safety and disease activity, but results are limited due to the very small number of participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common arthritis drug hold off a rare blood cancer?
- Can keytruda stop smoldering myeloma in its tracks?
- Simple lifestyle changes and a common heart drug may improve quality of life for myeloma patients
- New study asks: how do early blood disorders really affect daily life?
- Could a drug combo stop smoldering myeloma in its tracks?
- New drug cocktail aims to halt smoldering myeloma before it strikes